Skip to content
10-Q

Quarterly Report

Celldex Therapeutics, Inc. CLDX

0001410578-24-001766

← back to feed
Filed
Nov 6, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Oct 29, 2024 66.34M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $36.4M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $34.81M
Current Liabilities Q3 2024 · Sep 30, 2024 $32.09M
Current Liabilities Q3 2024 · Dec 31, 2023 $31.13M
Total Liabilities Q3 2024 · Sep 30, 2024 $37.27M
Total Liabilities Q3 2024 · Dec 31, 2023 $36.46M
Current Assets Q3 2024 · Sep 30, 2024 $778.84M
Current Assets Q3 2024 · Dec 31, 2023 $431.69M
Total Assets Q3 2024 · Sep 30, 2024 $823.18M
Total Assets Q3 2024 · Dec 31, 2023 $465.63M
Shares Diluted Q3 2024 · Sep 30, 2023 47.26K sh
Shares Diluted Q3 2024 · Sep 30, 2023 47.24K sh
Capex Q3 2024 · Sep 30, 2023 $1.15M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$74.76M
Stockholders Equity Q3 2024 · Sep 30, 2023 $246.72M
Stockholders Equity Q3 2024 · Jun 30, 2023 $277.54M
Stockholders Equity Q3 2024 · Mar 31, 2023 $302.74M
Stockholders Equity Q3 2024 · Dec 31, 2022 $326.2M
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.81
Eps Diluted Q3 2024 · Sep 30, 2023 −$2.08
Eps Basic Q3 2024 · Sep 30, 2023 −$0.81
Eps Basic Q3 2024 · Sep 30, 2023 −$2.08
Sga Expense Q3 2024 · Sep 30, 2023 $8.22M
Sga Expense Q3 2024 · Sep 30, 2023 $22.08M
Rd Expense Q3 2024 · Sep 30, 2023 $34.54M
Rd Expense Q3 2024 · Sep 30, 2023 $87.59M
Operating Income Q3 2024 · Sep 30, 2023 −$41.24M
Operating Income Q3 2024 · Sep 30, 2023 −$106.92M
Revenue Q3 2024 · Sep 30, 2023 $1.52M
Revenue Q3 2024 · Sep 30, 2023 $2.75M